Jollimex 50 Capsule contains Mexiletine 50 mg, a class 1B antiarrhythmic agent primarily used to manage ventricular arrhythmias. Mexiletine acts by blocking sodium channels in cardiac cells, thereby stabilizing the cardiac membrane and reducing abnormal electrical activity that can lead to irregular heartbeats. It is indicated for the treatment of life-threatening ventricular arrhythmias such as ventricular tachycardia and ventricular fibrillation, particularly in patients who are unresponsive to or intolerant of other antiarrhythmic therapies. Jollimex 50 is administered orally, with dosing individualized based on clinical response and patient tolerance. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and dyspepsia, as well as neurological symptoms like dizziness, tremors, or ataxia. Caution is advised in patients with hepatic impairment or pre-existing conduction abnormalities, and continuous monitoring of cardiac function is recommended during therapy. Mexiletine should be used under strict medical supervision due to its potential proarrhythmic effects. It is contraindicated in patients with known hypersensitivity to mexiletine or other class 1 antiarrhythmic agents. Jollimex 50 Capsule offers an effective option for managing serious ventricular arrhythmias, contributing to improved cardiac rhythm control and patient outcomes.